Literature DB >> 1154802

The fate of metronidazole and tis implications in chemotherapy.

R M Ings, J A McFadzean, W E Ormerod.   

Abstract

1. [14C]Metronidazole was rapidly absorbed from the gastro-intestinal tract of rats giving maximum blood levels of radioactivity, equivalent to 6-4 and 6-7 mug metronidazole per ml blood, 1 h after oral dosing. 2. There was rapid equilibration between blood and most tissues, although radioactivity was concentrated in the liver, kidney, gastro-intestinal tract and vaginal secretions. 3. The half-life of clearance of radioactivity from the majority of tissues was between 3 and 4 h, although it was longer in the skin (8 h) and gastro-intestinal tract (14 h). 4. Fourteen radioactive excretion products were detected in rat urine and all the major products were identified. These all contained a nitro group and represented 97 degrees of the total radioactivity excreted in urine. 5. Unchanged metronidazole was secreted throughout the entire length of the gastro-intestinal tract and into the vagina of rats. 6. A hypothesis has been proposed to explain the high clinical efficacy of metronidazole in treating trichomonal and amoebic infections.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1154802     DOI: 10.3109/00498257509052069

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  10 in total

1.  Metronidazole neuropathy.

Authors:  W G Bradley; I J Karlsson; C G Rassol
Journal:  Br Med J       Date:  1977-09-03

2.  Relation between concentrations of metronidazole and Bacteroides spp in faeces of patients with Crohn's disease and healthy individuals.

Authors:  A Krook; B Lindström; J Kjellander; G Järnerot; L Bodin
Journal:  J Clin Pathol       Date:  1981-06       Impact factor: 3.411

3.  Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.

Authors:  R P Bolton; M A Culshaw
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

4.  Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis.

Authors:  T K Daneshmend; M Homeida; C M Kaye; A A Elamin; C J Roberts
Journal:  Gut       Date:  1982-10       Impact factor: 23.059

5.  1H nuclear magnetic resonance study of metronidazole metabolism by perfused rat liver.

Authors:  H Allars; M D Coleman; R S Norton
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jul-Sep       Impact factor: 2.441

Review 6.  Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-11       Impact factor: 9.546

7.  Studies on the disposition of a 5-nitroimidazole in laboratory animals.

Authors:  A Barrow; S R Burford; T J Forrest; A J Hawkins; D A Rose; P M Stevens; C W Vose; C M Walls
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Apr-Jun       Impact factor: 2.441

8.  Influence of malnutrition on the disposition of metronidazole in rats.

Authors:  D Jung; A Shah
Journal:  Pharm Res       Date:  1986-12       Impact factor: 4.200

9.  Mechanism of toxicity of nitro compounds used in the chemotherapy of trichomoniasis.

Authors:  S N Moreno; R Docampo
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

10.  Disposition and Residue Depletion of Metronidazole in Pigs and Broilers.

Authors:  Yuanhu Pan; Jiliang Yi; Bo Zhou; Shuyu Xie; Dongmei Chen; Yanfei Tao; Wei Qu; Zhenli Liu; Lingli Huang; Zonghui Yuan
Journal:  Sci Rep       Date:  2017-08-03       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.